Welcome to eBiochemicals.
Directory
| Smiles | CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(NC2=CC=C(O)C=C2)=O)=C(C)CCC1 |
|---|---|
| Synonyms | N-(4-Hydroxyphenyl)retinamide; Retinoic acid p-hydroxyanilide; (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide |
| InChI | InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+ |
Fenretinide (4-HPR) is a synthetic retinoid deriverative.
| Fenretinide is a synthetic retinoid agonist. It is an antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. ......by AdooQ BioScience, LLC |
| Fenretinide is an orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiati ......by BOC Sciences |
| Fenretinide is a Vitamin A acid analog that displays antioxidant and antiproliferative activity. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types. ......by BioVision, Inc., |
| Fenretinide is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death. ......by MedChemexpress Co., Ltd. |
| Fenretinide is an orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types. This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. ......by MedKoo Biosciences, Inc. |
| Fenretinide (4-HPR) is a synthetic retinoid deriverative. 4-HBR is shown to exhibit binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death. ......by Target Molecule Corp. |
| Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids. Deuterated analog also available. ......by Tocris Bioscience Inc. |
| Appearance:Light yellow to yellow solid | EBNumber:EB000019104 |
| Store at or below -20 oC. | by LC Laboratoies |
| Soluble in DMSO at 90 mg/mL; soluble in ethanol at 25 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-5 μM; buffers, serum, or other additives may increase or decrease the aqueous solubility. | by LC Laboratoies |
| DMSO ≥100mg/mL Ethanol ≥100mg/mL | by MedChemexpress Co., Ltd. |
| Signaling Pathways | Metabolic Enzyme/Protease | Autophagy |
|---|
| Target | RAR/RXR | Autophagy |
|---|
| Research Area | Cancer |
|---|
| Indications | Dysplastic nevus syndrome | Prostate tumor | Hormone refractory prostate cancer | Breast tumor | Ovary tumor |
|---|
| Product Name | Sponsor & Collaborators | Indications | Start Date | End Date | Phase |
|---|---|---|---|---|---|
| Fenretinide | Eastern Cooperative Oncology Group | Dysplastic nevus syndrome | 1998/9/30 | 2000/3/31 | Phase 2 Clinical |
| Fenretinide | Prostate tumor | 2004/6/30 | 2009/1/1 | Phase 2 Clinical | |
| Fenretinide | Cancer Therapeutics Research Group | Hormone refractory prostate cancer | 2003/11/30 | 2011/2/1 | Phase 2 Clinical |
| Fenretinide | MD Anderson Cancer Center | Breast tumor | 1996/5/31 | 2003/1/31 | Phase 2 Clinical |
| Fenretinide | National Cancer Institute | Ovary tumor | 2001/9/30 | 2004/3/1 | Phase 2 Clinical |
| Fenretinide | - | Phase 3 |
| Hazard Symbols : T |
| Risk Statements : R60;R61;R20/21/22;R36/37/38 |
| Safety Statements : S52;S26;S36/37/39;S45 |
| RTECS : VH6420000 |
| WGKGermany : 3 |
| Company | Price and Availability | Country/Region |
|---|---|---|
| Abcam | 10mg/USD115() | USA |
| AdooQ BioScience, LLC | 25mg/USD120() | USA |
| Apexbio Technology LLC | 10mg/USD50(In stock) | USA |
| Ark Pharm, Inc. | USA | |
| BOC Sciences | ||
| BioVision, Inc., | USA | |
| Biochempartner Co., Ltd | China | |
| CHEMSCENE, LLC | 10mg/USD60();50mg/USD107() | USA |
| Carbosynth Limited | 10mg/USD95() | |
| Cayman Chemical Company | 5mg/USD39() | USA |
| Clearsynth Labs Limited | 25mg/USD120() | India |
| EMD Millipore | 5mg/USD149() | USA |
| LC Laboratoies | 10mg/USD39(In stock);25mg/USD64(In stock);50mg/USD89(In stock);100mg/USD121(In stock);250mg/USD233(In stock);500mg/USD335(In stock);1g/USD545(In stock);2g/USD915(In stock);5g/USD1990(In stock) | USA |
| Lancrix Chemicals. | 500mg/USD320() | China |
| MedChemexpress Co., Ltd. | 10mg/USD60();50mg/USD107() | USA |
| MedKoo Biosciences, Inc. | USA | |
| Santa Cruz Biotechnology, Inc. | 5mg/USD104() | USA |
| Selleck Chemicals LLC | USA | |
| Shanghai Haoyuan Chemexpress Co., Ltd. | 10mg/USD60();50mg/USD107() | China |
| Sigma-Aldrich, Inc. | 5mg/USD151() | USA |
| Target Molecule Corp. | 5mg/USD30();10mg/USD55();25mg/USD108();50mg/USD198() | USA |
| Tocris Bioscience Inc. | 10mg/USD139() | USA |
| Tokyo Chemical Industry Co., Ltd. | 10mg/USD94() | Japan |
| Name | CAS No | Formula | MW |
|---|
| Name | CAS No | Formula | MW |
|---|---|---|---|
| AGN 205728 | 859498-05-8 | C29H27NO3 | 437.53 |
| AGN 196996 | 958295-17-5 | C24H20BrNO5 | 482.32 |
| AGN 194310 | 229961-45-9 | C28H24O2S | 424.55 |
| Acitretin (sodium) | 925701-88-8 | C21H25NaO3 | 348.41 |
| Acitretin | 55079-83-9 | C21H26O3 | 326.43 |
| Adapalene (sodium salt) | 911110-93-5 | C28H27NaO3 | 434.5 |
| Adapalene | 106685-40-9 | C28H28O3 | 412.52 |
| TTNPB | 71441-28-6 | C24H28O2 | 348.48 |
| Magnolol | 528-43-8 | C18H18O2 | 266.33 |
| Tazarotene | 118292-40-3 | C21H21NO2S | 351.46 |
| LG 100268 | 153559-76-3 | C24H29NO2 | 363.49 |
| Isotretinoin | 4759-48-2 | C20H28O2 | 300.44 |
| Palovarotene | 410528-02-8 | C27H30N2O2 | 414.54 |
| Retinoic acid | 302-79-4 | C20H28O2 | 300.44 |
| AM580 | 102121-60-8 | C22H25NO3 | 351.44 |
| (R)-Flurbiprofen | 51543-40-9 | C15H13FO2 | 244.2609 |
| Tamibarotene | 94497-51-5 | C22H25NO3 | 351.44 |
| Bexarotene | 153559-49-0 | C24H28O2 | 348.48 |
| AGN 195183 | 367273-07-2 | C22H22ClF2NO4 | 437.86 |
| AR7 | 80306-38-3 | C15H12ClNO | 0.0 |
| Name | CAS No | Formula | MW |
|---|---|---|---|
| TAK-700 (R-form) | 752243-39-3 | C18H17N3O2 | 307.35 |
| Volasertib | 755038-65-4 | C34H50N8O3 | 618.81 |
| Olaparib | 763113-22-0 | C24H23FN4O3 | 434.46 |
| KX2-391 | 897016-82-9 | C26H29N3O3 | 431.53 |
| Toremifene | 89778-26-7 | C26H28ClNO | 405.96 |
| Toremifene (Citrate) | 89778-27-8 | C32H36ClNO8 | 598.08 |
| Bicalutamide | 90357-06-5 | C18H14F4N2O4S | 430.37 |
| IDO5L | 914471-09-3 | C9H7ClFN5O2 | 271.6356 |
| Enzalutamide | 915087-33-1 | C21H16F4N4O2S | 464.44 |
| Betulinic acid | 472-15-1 | C30H48O3 | 456.7 |
| Tivozanib | 475108-18-0 | C22H19ClN4O5 | 454.86 |
| Linsitinib | 867160-71-2 | C26H23N5O | 421.49 |
| Leuprolide (Acetate) | 74381-53-6 | C61H88N16O14 | 1269.45 |
| Retaspimycin | 857402-23-4 | C31H45N3O8 | 587.7 |
| Retaspimycin (Hydrochloride) | 857402-63-2 | C31H46ClN3O8 | 624.17 |
| Motesanib (Diphosphate) | 857876-30-3 | C22H29N5O9P2 | 569.44 |
| Bafetinib | 859212-16-1 | C30H31F3N8O | 576.6154 |
| LY2228820 | 862507-23-1 | C26H37FN6O6S2 | 612.74 |
| Veliparib | 912444-00-9 | C13H16N4O | 244.29 |
| Veliparib (dihydrochloride) | 912445-05-7 | C13H18Cl2N4O | 317.21 |
